Sugi Predict

Sugi Predict / Compounds / SCHEMBL4022922

SCHEMBL4022922

SCHEMBL4022922

CCCCC(CC)CNS(=O)(=O)c1ccc(CN(Cc2cccc(C(F)(F)F)c2)C(=O)C(=O)O)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.39
▸ SERPINE1 P05121 2/20 0.38
▸ PTGES O14684 2/20 0.38
▸ TRPV1 Q8NER1 1/20 0.36
▸ LMNA P02545 3/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TRPM8 Q7Z2W7 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ UBE2M P61081 2/20 0.34
▸ DCUN1D1 Q96GG9 2/20 0.34
▸ PTPN2 P17706 1/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ADAMTS4 O75173 1/20 0.34
▸ MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021417 0.88 LIMK2 (0.39) PTGESLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL4713478 0.88 NR1D1 (0.38) EPHX1TRPV1LMNAMAPTALDH1A1
SCHEMBL1854854 0.87 SMN1; SMN2 (0.42) EPHX1SERPINE1PTGESTRPV1LMNA
SCHEMBL4016045 0.87 SMN1; SMN2 (0.42) EPHX1SERPINE1PTGESTRPV1LMNA
SCHEMBL4711910 0.85 MAPT (0.40) EPHX1TRPV1LMNAMAPTRAB9A
SCHEMBL4711906 0.83 EPHX1 (0.38) EPHX1TRPV1LMNAMAPTALDH1A1
SCHEMBL4017082 0.82 SERPINE1 (0.40) SERPINE1PTGESLMNASMN1; SMN2TRPM8
SCHEMBL4024326 0.82 MAPK1 (0.46) SERPINE1PTGESLMNASMN1; SMN2ALDH1A1
SCHEMBL4018739 0.82 ALDH1A1 (0.36) LMNASMN1; SMN2MAPTALDH1A1NPSR1
SCHEMBL1852522 0.81 TRPM8 (0.43) EPHX1SERPINE1PTGESLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US claimed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 EPHX1 2172/4885SERPINE1 2212/4885PTGES 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.